A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VDPHL01 IN MALE SUBJECTS WITH ANDROGENETIC ALOPECIA

Status: Recruiting

Eligibility Criteria

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- male (based on sex at birth)
•18-65 years of age (inclusive) - clinical diagnosis of mild to moderate Androgenetic Alopecia (AGA 0

Exclusion Criteria:

- uncontrolled high blood pressure - history of heart disease

Conditions & Interventions

Interventions:
Drug: Placebo, Drug: VDPHL01
Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
AGA, androgenetic alopecia, Men's hair loss

More Information

Description: The research study will compare VDPHL01 with placebo (no active ingredient) to learn about the safety and how VDPHL01 works for men who have androgenetic alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens resulting in hair loss. VDPHL01 is an extended release (ER) oral (taken by mouth) form of minoxidil.
Study Contact: John Meisenheimer - jmeisenh@umn.edu
Principal Investigator: Maria Hordinsky
Phase: PHASE2
IRB Number: STUDY00024357